Has Michael Casey, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,307 in general payments to Michael Casey, MD across 789 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Casey, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Casey, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Casey, MD

Family Medicine · Slidell, LANPI 1356397103

Payments from drug & device makers

$13,307in general payments, 2019–2025

Across 789 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$2K
Novo Nordisk$2K
AstraZeneca$1K
Pfizer$1K
AbbVie$878
Lilly USA, LLC$716
plus $6K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	133	$1,957
Novo Nordisk	107	$1,541
AstraZeneca	27	$1,217
Pfizer	67	$1,005
AbbVie(2 entities)	61	$878
Lilly USA, LLC	48	$716
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	32	$523
Amgen	27	$411
Merck	27	$409
Boehringer Ingelheim	25	$405
Bayer	16	$379
Ironwood Pharmaceuticals, Inc	21	$369
Astellas Pharma US Inc	21	$358
Dexcom, Inc.	6	$268
Exact Sciences	15	$264
Novartis	15	$258
E.r. Squibb & Sons, L.L.C.	17	$255
Sanofi-aventis U.S. LLC	13	$196
Johnson & Johnson	11	$153
Takeda Pharmaceuticals U.S.A., Inc.	12	$153
Kowa Pharmaceuticals America, Inc.	9	$128
Sumitomo Pharma America, Inc.	7	$98
Mannkind Corporation	1	$90
Nestle Healthcare Nutrition Inc.	1	$86
Daiichi Sankyo Inc.	3	$73
Otsuka America Pharmaceutical, Inc.	4	$69
Silk Road Medical, Inc.	1	$68
Teva Pharmaceuticals USA, Inc.	5	$66
Paratek Pharmaceuticals, Inc.	4	$60
Eisai Inc.	4	$54
Phathom Pharmaceuticals, Inc.	4	$54
Sunovion Pharmaceuticals Inc.	4	$53
Boston Scientific	3	$50
Almatica Pharma LLC	3	$48
Amarin Pharma, Inc.	3	$47
Esperion Therapeutics, Inc.	3	$42
Saluda Medical Americas, Inc.	1	$42
Abbott	3	$41
Axsome Therapeutics, Inc.	2	$37
Corcept Therapeutics	2	$36
Inspire Medical Systems, Inc.	2	$35
Jazz Pharmaceuticals Inc.	2	$33
Amneal Pharmaceuticals LLC	2	$29
Edwards Lifesciences	1	$22
Sanofi	1	$20
Insulet Corporation	1	$20
Shire North American Group Inc	1	$20
Supernus Pharmaceuticals, Inc.	1	$20
Clarus Therapeutics Inc.	1	$18
IBSA Pharma Inc.	1	$18
Genentech USA, Inc.	1	$17
Ultragenyx Pharmaceutical Inc.	1	$16
Smith+Nephew	1	$16
Alfasigma USA, Inc.	1	$16
Vertex	1	$14
Biohaven Pharmaceutical Holding Company Ltd.	1	$13
Avanir Pharmaceuticals, Inc.	1	$13
Phadia US Inc.	1	$11

How this compares

$13,307 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$135,837

Medicare patients

535

Services billed

1,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Other family medicine in Slidell